(MENAFNEditorial)
The Belarusian market will suffer from the impact of depreciation and economic instability as the country's economy becomes ever more reliant on Russia n loans to function. Furthermore wage growth mandated by the government will become unsustainable threatening to dampen internal consumption. Belarus will present little reward for high risk for most pharmaceutical companies in the region.
Headline Expenditure Projections
Pharmaceuticals: BYR8927bn in 2013 (USD1.00bn) to BYR11490bn (USD1.09bn) in 2014; +28.7% in local currency terms and +9.2% in US dollar terms.
Full Report Details at
- http://www.fastmr.com/prod/924112_belarus_pharmaceuticals_healthcare_report_q1_2015.aspx?afid=101
Healthcare: BYR29768bn (USD3.34bn) in 2013 to BYR37249bn (USD3.55bn) in 2014; +25.1% in local currency terms and +6.1% in US dollar terms.
Risk/Reward Index
In our latest Pharmaceutical Risk/Reward Index (RRI) matrix Belarus is 14th out of the 20 countries surveyed in the Central and Easter Europe (CEE) region having considerably improved since the start of the year. However although its Rewards variables (and in particular its Industry Rewards) are favourable Belarus will continue to represent a very risky market on account of unresolved issues such as the lack of patent protection corruption and political tensions.
Key Trends And Developments
* Belarusian deputies have adopted amendments to the Law on Medicines. The amendments to the law will simplify procedures of medical product registration strengthen control over the quality of medicines and regulate prices. Under the current law registration is carried out every five years but the new law provides for the possibility of issuing a perpetual licence. The law also stipulates that only medication with an international certificate will enter the market and in a year the countries of the Eurasian Economic Union - ensuring that quality controls remain rigorous.
* Grindeks is considering building a plant in Russia or Belarus to serve its growing business in the CIS markets.
* Belarus is set to join the PIC/S Scheme and the...
The Belarus Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports focusing on the growth outlook for the prescription OTC patented drugs and generics market segments.
BMI's Belarus Pharmaceuticals & Healthcare Report provides industry professionals strategists company executives investors analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Belarusian pharmaceutical and healthcare industry.
Key Benefits
* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Belarus to test other views - a key input for successful budgeting and strategic business planning in the Belarusian pharmaceutical and healthcare market.
* Target business opportunities and risks in the Belarusian pharmaceutical and healthcare sector through our reviews of latest industry trends regulatory changes and major deals projects and investments in Belarus.
* Assess the activities strategy and market position of your competitors partners and clients via our Company Profiles (inc. SWOTs KPIs and latest activity) and Competitive Landscape Tables.
Coverage
BMI Industry View & Industry SWOT
An at-a-glance perspective on latest regulatory developments key forecast indicators and major corporate developments covering the prescription OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis and taken together with BMI's political economic and business environment SWOTS it gives a complete overview of market climate.
Market Summary
Snapshot of key market characteristics including total size of pharmaceuticals and healthcare segments growth drivers leading therapeutic areas and the competitive landscape.
Regulatory Regime
Details of the industry regulatory framework and key legislation covering the licensing of new products/services pricing and reimbursements intellectual property taxation and advertising as well as an analysis of the overall regulatory burden.
Industry Developments
Focus on government healthcare reforms epidemiological trends company M&As product launches market entries FDI activity R&D biotechnology clinical trials and supply chain issues.
BMI Industry Forecasts
Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions plus analysis of key downside risks to the main forecast including:
Healthcare: Total healthcare expenditure (US$bn) healthcare expenditure (% of GDP) healthcare expenditure per capita (US$) hospital beds (per `000 population) doctors (per `000 population) birth and mortality rate (per `000 population)
Pharmaceutical market: Drug expenditure (US$bn) drug expenditure (% of GDP) drug expenditure per capita (US$)
Patented drug market: Prescription drug sales (US$bn) prescription sales (% of total sales) sales broken down by 14 therapeutic areas (cardiovascular anti-infectives etc.)
Generic drug market: Generic product sales (US$bn) generic sales (% of total sales)
OTC drug market: OTC sales (US$bn) OTC sales (% of total sales) sales broken down by product types (analgesics skin treatments vitamins and minerals etc.)
Medical Devices: Medical device sales (US$bn) medical device sales (% of total healthcare market)
Macroeconomic Forecasts: Nominal and real GDP % real GDP growth % private consumption growth % industrial output growth % consumer price index % GDP price deflator exports imports trade balance current account balance foreign direct investment exchange rate against US$ government expenditure external debt.
Competitive Landscape
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector as well as the OTC generics and distribution sub-sectors.
Company Profiles
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts we provide quick and easy access to the best competitive intelligence available. Our unbiased expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.